Fig 1.
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Fig 2.
Assessment of the risk of bias of the included studies.
(A) Risk of bias graph. (B) Risk of bias summary.
Fig 3.
Funnel plot of the including studies evaluating the presence of publication bias.
Table 1.
Characteristics of RCTs.
Table 2.
Description of RCTs.
Fig 4.
Comparisons of doxorubicin alone vs experimental chemotherapy: Forest plots of 1-year overall survival.
M-H, Mantel-Haenszel; CI, confidence interval.
Fig 5.
Comparisons of doxorubicin alone vs experimental chemotherapy: Forest plots of overall survival.
M-H, Mantel-Haenszel; CI, confidence interval.
Table 3.
Summary of the meta-analysis.
Fig 6.
Comparisons of doxorubicin alone vs experimental chemotherapy: Forest plots of 6-month progression-free survival.
CI, confidence interval; M-H, Mantel-Haenszel.
Fig 7.
Comparisons of doxorubicin alone vs experimental chemotherapy: Forest plots of progression-free survival.
CI, confidence interval; M-H, Mantel-Haenszel.
Fig 8.
Comparisons of doxorubicin alone vs experimental chemotherapy: Forest plots of the incidence of severe nausea/vomiting adverse events.
CI, confidence interval; M-H, Mantel-Haenszel.
Fig 9.
Comparisons of doxorubicin alone vs doxorubicin-based combination chemotherapy: Forest plots of 1-overall survival.
M-H, Mantel-Haenszel; CI, confidence interval.
Fig 10.
Comparisons of doxorubicin alone vs doxorubicin-based combination chemotherapy: Forest plots of progression-free survival.
SE, standard error; IV, inverse variance; CI, confidence interval.
Fig 11.
Comparisons of doxorubicin alone vs doxorubicin-based combination chemotherapy: Forest plots of the overall incidence of severe adverse events.
M-H, Mantel-Haenszel; CI, confidence interval.